Tag: Coronavac
Brazil: previously infected and fully vaccinated subjects with high anti-S IgG titers are susceptible to infection by VOC
Here we show that even previously infected and fully vaccinated subjects with high anti-S IgG titers are susceptible to infection by VOC, highlighting that immune responses induced by either natural infection or vaccination may not be sufficient to prevent infection by SARS-CoV-2 variants.… ...More...
Singapore: significant risk of vaccine breakthrough with the Sinovac coronavirus vaccine
There is a significant risk of “vaccine breakthrough” with the Sinovac vaccine, or CoronaVac, with international evidence showing that many who had taken it were later infected with COVID-19, said the Ministry of Health’s (MOH) director of medical services Kenneth Mak on Friday, 18 June 2021.… ...More...
Sinovac coronavirus vaccine – 27.7% effective within the first two weeks, 56.5% effective two weeks after the second dose
The study by the University of Chile found inoculation to be 56.5 percent effective in protecting recipients two weeks after the second dose, and 27.7 percent effective within the first two weeks.… ...More...
Sinovac coronavirus vaccine “significantly less effective than what previous data suggested”
The São Paulo-based Butantan Institute – which is running final-stage clinical trials for CoronaVac, manufactured by Beijing-based Sinovac – submitted new data to Brazil’s health regulator on Tuesday, listing an efficacy rate of 50.4 per cent.… ...More...